SI-BONE, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SIBN research report →
Range $21 – $32
Price Chart
About the company
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally.
- CEO
- Laura A. Francis
- IPO
- 2018
- Employees
- 376
- HQ
- Santa Clara, CA, US
Get TickerSpark's AI analysis on SIBN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.07B
- P/E
- -74.76
- Fwd P/E
- 74.16
- PEG
- -1.35
- P/S
- 4.74
- P/B
- 5.63
- EV/EBITDA
- -269.34
- Div Yield
- 0.00%
- Gross Margin
- 79.40%
- Op Margin
- -7.57%
- Net Margin
- -6.20%
- ROE
- -7.57%
- ROIC
- -7.35%
Latest fiscal year · YoY change
- Revenue
- $200.93M+20.2%
- Gross Profit
- $159.88M+21.0%
- Op Income
- $-22,330,000
- Net Income
- $-18,908,000+38.8%
- EPS
- $-0.44+41.3%
- OCF Growth
- +94.6%
- FCF Growth
- +60.3%
- 52W High
- $25.92
- 52W Low
- $11.48
- 50D MA
- $20.78
- 200D MA
- $16.90
- Beta
- 0.64
- RSI (14)
- 58
- Avg Volume
- 717.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SI-BONE posted a solid third quarter with 15% revenue growth, 20% U.S. procedure growth, improving margins and cash flow, while highlighting Onyx and new reimbursement as major long-term catalysts.· November 2, 2026
- Worldwide revenue rose 14.5% to $55.7 million; U.S. revenue grew 13.9% to $52.8 million on 19.5% procedure growth.
- Gross profit increased 13.7% to $44.2 million and gross margin was 79.3%; net loss narrowed to $3.6 million, or $0.08 per share.
- Adjusted EBITDA climbed 32.4% to $3.0 million, with a 5.5% margin; year-to-date operating cash flow improved to about $4.4 million from $2.4 million used last year.
- Management reaffirmed 2026 revenue guidance of $231 million to $233 million and 79% gross margin, while lowering full-year operating expense growth to 10.5% from 12%.
- Onyx alpha launch is tracking ahead of Granite’s early launch, and new DRGs plus potential NTAP could further expand reimbursement and procedure economics.
SI-BONE reported third-quarter 2026 worldwide revenue of $55.7 million, up 14.5% year over year, and U.S. revenue of $52.8 million, up 13.9%. Gross profit was $44.2 million, up 13.7%, and gross margin was 79.3%. Net loss narrowed to $3.6 million, or $0.08 per diluted share, versus a loss of $4.6 million, or $0.11 per share, a year ago. Adjusted EBITDA was $3.0 million, up 32.4%, with a 5.5% margin. For 2026, management reaffirmed revenue guidance of $231 million to $233 million and gross margin of 79%, and reduced expected operating expense growth to 10.5% from 12%. Management said the midpoint of full-year guidance implies over 20% year-over-year revenue growth in Q4.
Laura Francis framed the quarter as evidence that SI-BONE’s multiyear strategy is working, citing accelerating procedure demand, broader physician adoption and expanding use cases beyond the pelvis. She emphasized that Onyx, the new Granite DRGs, and deeper penetration with interventional spine physicians create what she called a defining moment for the company. Her tone was confident and upbeat, with repeated references to strong early interest in Onyx and confidence in durable long-term growth.
Anshul Maheshwari focused on operating leverage and conversion of growth into profitability and cash. He highlighted 79.3% gross margin, $44.2 million of gross profit, $3.0 million of adjusted EBITDA, and year-to-date operating cash flow of about $4.4 million versus $2.4 million used in the prior year period. He also noted $146.3 million in cash and equivalents and said 2026 operating expense growth is now expected to be 10.5%, reflecting efficiency even as the company invests in Onyx, R&D and commercial expansion.
Analysts pressed management on how quickly Onyx can scale, whether the launch can support growth beyond the current consensus, and what early surgeon feedback looks like. Management said early Onyx demand is tracking ahead of Granite’s comparable launch period, with use coming both in Granite cases and in non-pelvic cases, and that training is straightforward because Onyx is a line extension. Questions also focused on pricing/ASP, gross margin, and reimbursement; management said ASP should improve in Q4 as Onyx mix builds and Granite cases with more implants increase, while gross margin may face modest pressure in 2027 from added Onyx capacity and depreciation.
The bull case from this call is that SI-BONE is showing strong underlying procedure momentum across multiple call points, not just one product or one channel. Management believes Onyx, better reimbursement for Granite, and expanding interventional adoption can all compound growth, with early indicators already running ahead of prior launches.
The main risks discussed were that Onyx is still in alpha launch, so meaningful revenue contribution remains early and execution will take time. Management also flagged potential ASP pressure from mix shifts, modest gross margin pressure in 2027 from new capacity, and the fact that some reimbursement changes and NTAP timing are still pending or not yet fully realized.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.7%
- Shares Outstanding
- 45.11M
- Float Shares
- 40.46M
of shares held by institutions
173 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Light Asset Management, LLC | 7.69M | ▼ 440.64K |
| Cadian Capital Management, LP | 3.79M | ▲ 443.92K |
| Blackrock, Inc. | 3.72M | ▲ 47.57K |
| American Century Companies Inc | 2.52M | ▲ 9.87K |
| Vanguard Group Inc | 2.50M | ▲ 11.57K |
| Brown Advisory Inc | 1.95M | ▼ 125.88K |
| Vanguard Capital Management LLC | 1.89M | ▲ 52.03K |
| Impax Asset Management Group PLC | 1.43M | 0 |
| Gilder Gagnon Howe & Co LLC | 1.33M | ▲ 72.25K |
| Nuveen, LLC | 1.32M | ▲ 298.31K |
| State Street Corp | 1.24M | ▲ 28.14K |
| Paradigm Capital Management Inc/Ny | 1.23M | ▼ 5.00K |
Held by 225 ETFs
Biggest fund positions in SIBN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | FRANCIS LAURA | sell | 3,892 |
| Nov 16, 26 | FRANCIS LAURA | sell | 2,235 |
| Nov 16, 26 | FRANCIS LAURA | sell | 3,203 |
| Nov 16, 26 | FRANCIS LAURA | sell | 3,651 |
| Nov 16, 26 | FRANCIS LAURA | sell | 1,972 |
| Nov 17, 26 | FRANCIS LAURA | sell | 1,901 |
| Nov 16, 26 | PISETSKY MICHAEL A. | sell | 1,854 |
| Nov 16, 26 | PISETSKY MICHAEL A. | sell | 1,871 |
| Nov 16, 26 | Maheshwari Anshul | sell | 2,476 |
| Nov 16, 26 | Maheshwari Anshul | sell | 2,189 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SIBN coverage
Recent articles, reports, and earnings notes.
No research on SIBN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SIBN report →SI-BONE To Present at Piper Sandler 38th Annual Healthcare Conference on December 1, 2026
globenewswire.com · Nov 19
Are You Looking for a Top Momentum Pick? Why Si-Bone (SIBN) is a Great Choice
zacks.com · Nov 12
SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
SiBone (SIBN) Hit a 52 Week High, Can the Run Continue?
zacks.com · Nov 5
SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
SiBone Q3 Earnings Call Highlights
marketbeat.com · Nov 2
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 2
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
globenewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.